常州千红生化制药股份有限公司 股票代码：002550 证券简称：千红制药 Changzhou Qianhong Biopharma Co., Ltd. （常州市新北区云河路518号） 向不特定对象发行可转换公司债券 募集资金使用可行性分析报告 （修订稿） 二〇二五年十一月 本报告中如无特别说明，相关用语或简称具有与《常州千红生化制药股份有 限公司向不特定对象发行可转换公司债券预案（修订稿）》中相同的含义。 一、本次募集资金使用计划 公司拟向不特定对象发行可转换公司债券（以下简称"可转债"）募集资金 总额不超过人民币 100,000.00 万元（含本数），扣除发行费用后的募集资金净额 将用于投入以下项目： | | | 单位：万元 | | | --- | --- | --- | --- | | 序 | 项目名称 | 拟使用募集资金 项目投资总额 | | | 号 | | | 投入金额 | | 1 | 创新药研发项目 | 41,923.49 | 41,000.00 | | 2 | 湖北钟祥原料药生产基地一期建设项目 | 33,000.00 | 30,000.00 | | 3 | 补充流动资金 | 29,000.00 ...

关于向不特定对象发行可转换公司债券摊薄即期回报与 填补措施及相关主体承诺（修订稿）的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或者重大遗漏。 重要提示： 本公告中关于常州千红生化制药股份有限公司（以下简称"千红制药"、"公 司"）本次向不特定对象发行可转换公司债券后对公司主要财务指标的分析、描 述均不构成公司的盈利预测，且关于填补回报措施及相关承诺主体的承诺不等 于对公司未来利润做出保证，投资者不应仅依据该等分析、描述进行投资决策， 如投资者据此进行投资决策而造成任何损失的，公司不承担任何责任。提请广 大投资者注意。 公司拟向不特定对象发行可转换公司债券（以下简称"本次发行"）。根据《国 务院办公厅关于进一步加强资本市场中小投资者合法权益保护工作的意见》（国 办发〔2013〕110 号）、《国务院关于进一步促进资本市场健康发展的若干意见》 （国发〔2014〕17 号）和中国证券监督管理委员会（以下简称"中国证监会"） 《关于首发及再融资、重大资产重组摊薄即期回报有关事项的指导意见》（证监 会公告〔2015〕31 号）等相关文件的要求，为保障中小投资者利益，公司就 ...

常州千红生化制药股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002550 证券简称：千红制药 公告编号：2025-042 重要提示： 常州千红生化制药股份有限公司（以下简称"千红制药"或"公司"）于 2025 年 11 月 24 日召开了第六届董事会第十二次会议，会议决定于 2025 年 12 月 10 日召开公司 2025 年第二次临时股东会，本次股东会采用现场投票与网络投票相结合的方式进行。现发布关 于召开公司 2025 年第二次临时股东会的通知如下： 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法 律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 10 日 14:30 （2）网络投票时间：通过深圳证券交 ...

常州千红生化制药股份有限公司 2025 年第二次临时股东会议案汇编 常州千红生化制药股份有限公司 江苏省常州市新北区云河路 518 号 2025 年第二次临时股东会议案汇编 股票简称：千红制药 股票代码：002550 | | | | 对象发行可转换公司债券相关事宜的议案 87 | | --- | 鉴于本次公司向不特定对象发行可转换公司债券工作的实际进展情况及公 司对募集资金项目作出的调整方案，公司于 2025 年 11 月 24 日召开第六届董事会 第十二会议，同意公司根据实际情况对本次向不特定对象发行可转换公司债券预 案及相关文件作出调整。 本次修订的主要内容如下： 本次募集资金用途 本次发行可转换公司债券的募集资金总额不超过人民币 100,000.00 万元（含 本数），扣除发行费用后，拟用于以下项目： | | | 单位：万元 | | | --- | --- | --- | --- | | 序 | 项目名称 | 拟使用募集资金 项目投资总额 | | | 号 | | 投入金额 | | | 1 | 创新药研发项目 | 41,923.49 | 41,000.00 | | 2 | 湖北钟祥原料药生产基地一期建设项 ...

证券代码：002550 证券简称：千红制药 公告编号：2025-038 常州千红生化制药股份有限公司 二、董事会会议审议情况 本次董事会会议形成决议如下： （一）审议并通过了《关于调整公司向不特定对象发行可转换公司债券方 案的议案》 表决结果：9 票同意，0 票弃权，0 票反对，议案获得通过。 本次调整的主要内容为本次募集资金用途，具体如下： 第六届董事会第十二次会议决议公告 本次发行可转换公司债券的募集资金总额不超过人民币 100,000.00 万元（含 本数），扣除发行费用后，拟用于以下项目： 本公司及董事会全体成员保证信息披露内容的真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 单位：万元 一、董事会会议召开情况 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）第六届 董事会第十二次会议通知于 2025 年 11 月 19 日通过邮件方式发出，会议于 2025 年 11 月 24 日在公司会议室以现场结合通讯表决的方式召开，会议应出席董事 9 人，实际出席董事 9 人，其中宁敖先生、任胜祥先生、高玉玉女士以通讯表决方 式出席。会议由董事长王耀方先生召集并主持。本次会议的通知、召开以 ...

Core Viewpoint - Qianhong Biopharma's stock price has shown significant volatility, with a year-to-date increase of 38.42%, but recent declines in the short term indicate potential market concerns [1][2]. Company Overview - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province. The company specializes in the research, production, and sales of various pharmaceutical products, including lyophilized powders, injections, tablets, and active pharmaceutical ingredients [2]. - The company's main revenue sources are from its formulation series (62.97%) and active pharmaceutical ingredients (36.70%), with a minor contribution from other products (0.33%) [2]. Financial Performance - For the period from January to September 2025, Qianhong Biopharma reported a revenue of 1.215 billion yuan, reflecting a year-on-year growth of 0.61%. The net profit attributable to the parent company was 383 million yuan, marking a significant increase of 23.79% [2]. - The company has distributed a total of 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the past three years [2]. Market Activity - As of November 24, Qianhong Biopharma's stock price was 8.42 yuan per share, with a market capitalization of 10.776 billion yuan. The stock experienced a trading volume of 101 million yuan and a turnover rate of 1.29% [1]. - The stock has been active on the "Dragon and Tiger List" seven times this year, indicating notable trading interest, with the most recent appearance on August 7, where it recorded a net buy of 10.2288 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 73,600, with an average of 12,785 circulating shares per person, a slight decrease of 1.15% from the previous period [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 49.0352 million shares, which increased by 19.8701 million shares compared to the previous period [2].

千红制药公告，持股5%以上股东赵刚及其一致行动人原计划在披露后15个交易日后的3个月内以集中竞 价或大宗交易减持不超2090万股，占总股本1.6331%。截至2025年11月21日，已通过集中竞价减持 604.76万股，占0.4725%，均价8.5元/股，减持价格区间8.26元/股至8.62元/股。上述股东决定提前终止减 持计划，当前合计持有8186.54万股，占6.3967%。 ...

常州千红生化制药股份有限公司 证券代码：002550 证券简称：千红制药 公告编号：2025-037 关于持股 5%以上股东及其一致行动人减持股份变动触及 1%整数 倍暨减持计划提前终止的公告 持股 5%以上的股东赵刚先生及其一致行动人赵人谊、建信基金 -赵人谊-建信鑫享 1 号单一资产管理计划均保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 常州千红生化制药股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 7 日披露了《关于持股 5%以上股东及其一致行动人减持股份的预披露公 告》（公告编号：2025-021），合计持有公司股份 72,913,021 股（占公司目前总 股本比例 5.6972%，占公司剔除回购专用账户持股数量的总股本比例 5.8340%） 的大股东赵刚先生及其一致行动人建信基金-赵人谊-建信鑫享 1 号单一资产管 理计划，计划自上述公告披露之日起 15 个交易日后的 3 个月内以集中竞价或大 宗交易方式减持公司股份不超过 20,900,000 股（占公司总股本比例 1. ...

Core Viewpoint - Qianhong Biopharma's stock price has experienced fluctuations, with a year-to-date increase of 44.17%, but a recent decline in the last five trading days by 4.57% [1] Group 1: Company Overview - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province [2] - The company specializes in the research, production, and sales of various pharmaceutical products, including freeze-dried powders, injections, tablets, and raw materials [2] - The main revenue composition is 62.97% from formulations and 36.70% from raw materials [2] Group 2: Financial Performance - For the period from January to September 2025, Qianhong Biopharma achieved a revenue of 1.215 billion yuan, reflecting a year-on-year growth of 0.61%, and a net profit of 383 million yuan, up 23.79% year-on-year [2] - Cumulatively, the company has distributed 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the last three years [3] Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased to 73,600, with an average of 12,785 circulating shares per person, a decrease of 1.15% from the previous period [2] - The stock has appeared on the "Dragon and Tiger List" seven times this year, with the most recent instance on August 7, where it recorded a net purchase of 10.2288 million yuan [1]

Investment Rating - The report indicates a positive outlook for the CXO and research services sectors within the pharmaceutical industry, suggesting continued high growth potential [2][3]. Core Insights - The pharmaceutical industry saw a slight decline in sales revenue and a modest increase in net profit for Q3 2025 compared to Q3 2024, with revenue growth rates of -0.1% and net profit growth of 3.0% [2][16]. - The fastest-growing segments in terms of revenue for Q3 2025 were CXO, research services, and pharmaceuticals, while the fastest-growing segments for net profit were research services, CXO, and pharmacies [2][24]. - The report emphasizes the importance of innovative drugs, highlighting that 58 selected innovative drug companies in A-shares experienced a revenue growth of 1.4% and a net profit decline of 4.5% year-on-year for the first three quarters of 2025 [2][28]. - The research services sector showed significant improvement, with a revenue growth of 10.48% and net profit growth of 49.57% in Q3 2025 compared to Q3 2024, indicating a recovery in demand and market conditions [2][3]. Summary by Sections 1. Pharmaceutical Industry - The overall profitability of the pharmaceutical industry showed a slight improvement in Q3 2025, with a net profit margin increase compared to the same period in 2024 [7][17]. 2. Innovative Drugs - Innovative drug companies reported a revenue growth of 3.3% and a net profit decline of 15.0% in Q3 2025, with a focus on companies like Heng Rui Medicine and Rejane Bio [2][28]. 3. Traditional Chinese Medicine - The revenue and net profit growth for traditional Chinese medicine companies remained under pressure, with Q3 2025 showing a revenue decline of 1.1% year-on-year [2][3]. 4. Pharmaceuticals - The pharmaceutical sector experienced a revenue growth of 5.6% and a net profit growth of 12.5% in Q3 2025, indicating a recovery phase [2][3]. 5. Research Services - The research services sector demonstrated strong growth, with a revenue increase of 10.48% and net profit increase of 49.57% in Q3 2025, reflecting a positive market trend [2][3]. 6. Medical Services - Medical services companies faced challenges, with a slight revenue decline of 0.29% in Q3 2025, indicating ongoing pressure from macroeconomic factors [2][3]. 7. Medical Devices - The medical device sector reported a revenue growth of 3.30% in Q3 2025, with expectations for recovery in demand in the coming year [2][3]. 8. Biological Products - The biological products sector continued to face challenges, with a revenue decline of 14.5% in Q3 2025 compared to Q3 2024 [3]. 9. CXO - The CXO sector showed robust growth, with revenue increasing by 11.74% and net profit by 47.47% in Q3 2025, driven by improved market conditions [3]. 10. Raw Materials - The raw materials sector experienced a revenue decline of 8.2% in Q3 2025, influenced by geopolitical factors and reduced domestic demand [3]. 11. Pharmacies - Pharmacy companies reported a revenue growth of 1.9% in Q3 2025, with a focus on profit growth [3]. 12. Pharmaceutical Distribution - The pharmaceutical distribution sector showed a revenue growth of 1.7% in Q3 2025, with increasing industry concentration [3].